ABBOTT BIOTECHNOLOGY LTD. Patent applications |
Patent application number | Title | Published |
20130243786 | TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS (JRA) - Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described. | 09-19-2013 |
20130096938 | MANAGING HEALTHCARE SERVICES - System and method for facilitating a medical order/prescription of a prescription product, including a memory device to store predefined forms for the prescription product corresponding to a plurality of providers. A receiver receives prescription product information for the prescription product, patient intake information for the patient, including provider information for the patient, and a benefits summary related to the patient. A transmitter transmits the benefits verification request. A processor can be configured to generate the benefits verification request for the patient based on the patient intake information, select one of the predefined forms based on at least the patient provider information, populate at least one field of the selected predefined form based on the user intake information, and release the populated predefined form to facilitate a medical order/prescription of the prescription product to the patient. | 04-18-2013 |
20130004507 | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES - Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 01-03-2013 |
20120282270 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 11-08-2012 |
20120263731 | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS - The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof. | 10-18-2012 |
20120251550 | Crystalline anti-hTNFalpha antibodies - The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions. | 10-04-2012 |
20120233834 | SYSTEMS, DEVICES AND METHODS FOR ASSEMBLING AUTOMATIC INJECTION DEVICES AND SUB-ASSEMBLIES THEREOF - Exemplary embodiments provide automated assembly systems, devices and methods for assembling components for use in forming an automatic injection device. Exemplary assembly systems monitor, in real time, the frictional forces experienced as a plurality of components are assembled. The detected forces are used in providing real-time feedback to automatically control the assembly process and to determine whether the components are assembled properly. | 09-20-2012 |
20120219564 | Human Antibodies That Bind Human TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 08-30-2012 |
20120197209 | RELATED TO AUTOMATIC INJECTION DEVICES - An injection device comprises a syringe extendible against a spring bias from a retracted position in a housing to a projecting injecting position. A spring biased plunger has collapsible elbows which, when the plunger is released, initially engage the end of the syringe to drive it to the projecting position, whereupon arresting of the syringe movement causes the elbows to collapse inside the syringe to allow the plunger to engage and drive the bung. | 08-02-2012 |
20120178107 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 07-12-2012 |
20120177596 | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES - Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 07-12-2012 |
20120129185 | METHODS AND COMPOSITIONS FOR DIAGNOSING ANKYLOSING SPONDYLITIS USING BIOMARKERS - The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker. | 05-24-2012 |
20110313398 | AUTOMATIC INJECTION DEVICES - An injection device comprises a syringe extendible against a spring bias from a retracted position in a housing to a projecting injecting position. A spring biased plunger has collapsible elbows which, when the plunger is released, initially engage the end of the syringe to drive it to the projecting position, whereupon arresting of the syringe movement causes the elbows to collapse inside the syringe to allow the plunger to engage and drive the bung. | 12-22-2011 |
20110054414 | Automatic Injection Device - Exemplary embodiments provide a syringe plunger formed of a polymeric material. The syringe plunger includes a pressurizer disposed at a proximal end, and a distal end bifurcated into a first plunger arm having a first conical surface and a second conical surface, and a second plunger arm having a first conical surface and a second conical surface. The distal end includes a first contact surface defined by the first conical surface of the first plunger arm and the first conical surface of the second plunger arm, the first contact surface configured to initially contact a firing engagement mechanism, the first contact surface disposed at a first angle of between about 40° and about 80° relative to a longitudinal axis of the syringe plunger. The distal end also includes a second contact surface defined by the second conical surface of the first plunger arm and the second conical surface of the second plunger arm, the second contact surface configured to contact the firing engagement mechanism subsequent to contact by the first contact surface. | 03-03-2011 |
20100278822 | STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES - The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration. | 11-04-2010 |
20100016557 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 01-21-2010 |